Meet The People

 

Dr. Meyerson

Matthew Meyerson, M.D., PhD.

Professor of Pathology
Dana-Farber Cancer Institute and Harvard Medical School
Senior Associate Member, Broad Institute

M.D., Harvard Medical School, 1993
Ph.D., Harvard University, 1994

The goal of our laboratory is to improve the treatment of human cancer and to extend the lives of cancer patients, with a particular focus on lung cancer. Our approaches are cancer genomics and genome-inspired drug discovery. In addition, we seek to find infectious agents that cause hitherto mysterious human diseases.

As a principal investigator and mentor, my goals are to catalyze new fields of cancer research, and to mentor a new generation of cancer researchers.

“... Truth is not a colored bird to be chased among the rocks and captured by its tail, but a skeptical attitude towards life.” – Sinclair Lewis

matthew_meyerson@dfci.harvard.edu
617-632-4768

Dr. Meyerson

Julie Hammond-Coiro

Assistant to Dr. Matthew Meyerson
Dana-Farber Cancer Institute

My goal is to make the world a better place one step, one smile, and one act of kindness at a time.

“You give but little when you give of your possessions. It is when you give of yourself that you truly give.” – Kahlil Gibran

JulieM_Hammond-Coiro@dfci.harvard.edu
617-632-4377

Areas of Research

Cancer genomics: We use genomic approaches to interrogate somatic alterations in cancers, with a special focus on lung carcinoma, the #1 cause of cancer mortality worldwide. Based at Dana-Farber Cancer Institute and the Broad Institute, our group heads the investigation of somatic copy number alterations in cancer, as part of The Cancer Genome Atlas (TCGA) program of the NIH. These efforts, in conjunction with our other genome characterization methods, have uncovered novel copy number changes, gene mutations and translocations in a variety of cancer genomes and have fueled an exponential increase in our understanding of the biology of cancer evolution, spread and response to therapy.

Functional genomics: We pair our genome-discovery efforts with biochemical and molecular approaches, using lung cancer cell lines and transgenic mouse models. We especially seek to deepen our understanding of oncogenic signaling by pathways subject to genomic alteration in lung cancers, including the EGFR, FGFR and Ras pathways, pathways via the lineage oncogenes NKX2-1 and SOX2, and RNA splicing alterations, to reveal mechanisms that drive response or resistance to conventional and targeted therapy. Our goal is to use these discoveries of novel cancer vulnerabilities to develop a new generation of effective mutant-specific therapies.

Pathogen discovery: We have developed a cloud-based computational pipeline, termed PathSeq, to detect non-human DNA sequences in human diseased tissue samples, including—but not limited to—cancer. Notably, via application of PathSeq, we have uncovered a role for Fusobacterium nucleatum in pathogenesis of colon carcinoma and revealed a hitherto undiscovered bacterial species—since named Bradyrhizobium enterica—as being associated with human cord colitis syndrome. We are now expanding our investigations to explore possible pathogenic bases for human diseases of unknown origin.

Contact Us

Meyerson Laboratory
Dana 15
Dana-Farber Cancer Institute
450 Brookline Ave
Boston, MA 02215


Telephone: 617-632-4377
FAX: 617-582-7880
E-mail: info@dfci.harvard.edu